Researcher.Life Logo

mAbs : Impact Factor & More

eISSN: 1942-0870pISSN: 1942-0862
JournalOpen Access

Aims and Scope of mAbs

mAbs is a peer-reviewed multi-disciplinary scientific journal established in 2009, published by Taylor & Francis and dedicated to the art and science of antibody research and development. Its editor-in-chief is Janice M. Reichert and it is affiliated with The Antibody Society. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics. It is indexed in MEDLINE, PubMed, the Science Citation Index Expanded, Biological Abstracts, BIOSIS Previews, and Scopus. Less

Key Metrics

CiteScore
10.2
Eigenfactor
0.01 - 0.05
Impact Factor
5 - 10
SJR
Q1Immunology
SNIP
1.55
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on mAbs

mAbs Journal Specifications

Overview
Publisher TAYLOR & FRANCIS INC
Language English
Frequency Bi-monthly
Article Processing ChargesGBP 2915
Publication Time8
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year2009
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 8
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in mAbs ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in mAbs

Multi-modal feature learning to prioritize ADCs with favorable half-life in mice
  • 31 Dec 2026
  • mAbs
Discovery, development, and characterization of SPY002 and SPY072, two novel extended half-life monoclonal antibodies targeting TL1A: in vitro properties, in vivo pharmacology, pharmacokinetics, and preclinical safety
  • 31 Dec 2026
  • mAbs
AbDist: a lightweight, distance-based model for antibody affinity prediction as an interpretable benchmark for machine learning models
  • 31 Dec 2026
  • mAbs
Structure-based calculation of excipient effects on the viscosity of concentrated antibody solutions
  • 31 Dec 2026
  • mAbs
Dual agonism and selective T-cell depletion activity of a PD-1-directed antibody for treating autoimmune diseases
  • 31 Dec 2026
  • mAbs
Machine learning predictions of IgG1 and IgG4 self-association and high-concentration solution properties
  • 31 Dec 2026
  • mAbs
Multi-modal feature learning to prioritize ADCs with favorable half-life in mice
  • 31 Dec 2026
  • mAbs
Discovery, development, and characterization of SPY002 and SPY072, two novel extended half-life monoclonal antibodies targeting TL1A: in vitro properties, in vivo pharmacology, pharmacokinetics, and preclinical safety
  • 31 Dec 2026
  • mAbs
AbDist: a lightweight, distance-based model for antibody affinity prediction as an interpretable benchmark for machine learning models
  • 31 Dec 2026
  • mAbs
Structure-based calculation of excipient effects on the viscosity of concentrated antibody solutions
  • 31 Dec 2026
  • mAbs
Dual agonism and selective T-cell depletion activity of a PD-1-directed antibody for treating autoimmune diseases
  • 31 Dec 2026
  • mAbs
Machine learning predictions of IgG1 and IgG4 self-association and high-concentration solution properties
  • 31 Dec 2026
  • mAbs

FAQs on mAbs